EUCTR2021-005575-40-BE招募中1 期
A phase II study to evaluate the imaging potential of 68GaNOTA-Anti-MMR VHH2 for in vivo imaging of MMR-expressing Macrophages by means of Positron Emission Tomography (PET) in patients with non-small cell lung cancer (NSCLC).
Z Brussel0 个研究点目标入组 20 人开始时间: 2022年11月10日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •- Patients who have given informed consent
- •- Patients at least 18 years old
- •- Patient with local, locally advanced or metastatic disease of lung cancer, who is planned for resection or surgical biopsy of at least one lesion. In order to minimize partial volume effect the diameter of the tumor to be resected or biopsied should be = 10 mm in short axis for invaded adenopathies and = 10 mm in long axis for all other types of lesions.
- •- Patients who participated already in this study can be included if the subject meets all of the inclusion and none of the exclusion criteria at time of second inclusion.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •- Eastern Cooperative Oncology Group (ECOG) performance status 3 or higher.
- •- Pregnant patients
- •- Breast feeding patients
- •- Patients with any serious active infection
- •- Patient who have any other life-threatening illness or organ system dysfunction, which in the opinion of the investigator would either compromise patient safety or interfere with the evaluation of the safety of the best radiopharmaceutical
- •- Patients who are unlikely to cooperate with the requirements of the study
- •- Patients who are unwilling and/or unable to give informed consent
- •- Patients with increased risk of death from a pre-existing concurrent illness
研究者
相似试验
进行中（未招募）
1 期
Imaging study evaluating the utility of pre-treatment zirconium-89 labelled trastuzumab PET/CT (Imaging of the membranair receptor HER2 with the tracer zirconium 89 trastuzumab) and an early FDG-PET/CT response (early metabolic assessment) to identify patients with HER-2 positive invasive carcinoma of the breast with locally recurrent (not amenable to resection with curative intent) or metastatic disease unlikely to benefit from a novel anti-HER2 therapy: T-DM1EUCTR2011-005437-39-BEJules Bordet Institute105
进行中（未招募）
1 期
Imaging study evaluating the utility of pre-treatment zirconium-89 labelled trastuzumab PET/CT (Imaging of the membranair receptor HER2 with the tracer zirconium 89 trastuzumab) and an early FDG-PET/CT response (early metabolic assessment) to identify patients with HER-2 positive invasive carcinoma of the breast with locally recurrent (not amenable to resection with curative intent) or metastatic disease unlikely to benefit from a novel anti-HER2 therapy: T-DM1ocally recurrent (not amenable to resection with curative intent) or metastatic disease scheduled for a first or any subsequent metastatic treatment lineMedDRA version: 19.0Level: PTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-005437-39-NLJules Bordet Institute105
已完成
2 期
A phase II prospective imaging study evaluating the utility of pre-treatment zirconium-89 labelled trastuzumab PET/CT and an early FDG-PET/CT response to identify patients with advanced HER-2 positive breast cancer unlikely to benefit from a novel anti-HER2 therapy: T-DM1HER2 positive breast cancer10006291Breast cancerNL-OMON43903Institut Jules Bordet55
已完成
1 期
Dose-escalation Study of a Contrast Agent for Delineation of Urological Anatomy in Minimally Invasive SurgeryIntraoperative Ureter InjuryNCT03106038Li-Cor, Inc.41
进行中（未招募）
1 期
Phase II study to evaluate 68GaNOTA-Anti-MMR-VHH2 , a new tracer for positron emission tomography (PET/CT) of macrophages in oncological, hematological and cardiovascular diseases.EUCTR2020-002483-31-BEZ Brussel140